Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Mar 14;329(10):797-799.
doi: 10.1001/jama.2023.1053.

Rate-Adaptive Pacing for Heart Failure With Preserved Ejection Fraction

Dalane W Kitzman  1 , Bharathi Upadhya  2 , Ambarish Pandey  3
Affiliations
Editorial

Rate-Adaptive Pacing for Heart Failure With Preserved Ejection Fraction

Dalane W Kitzman et al. JAMA. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures:

Dr Kitzman reported receiving consulting fees from Bayer, Medtronic, Corvia Medical, Boehringer Ingleheim, Keyto, Rivus, NovoNordisk, AstraZeneca, and Pfizer; holding stock in Gilead; and receiving grants to his institution from Bayer, NovoNordisk, AstraZeneca, Rivus, and Pfizer. Dr Upadhya reported receiving grant funding from Corvia Medical. Dr Pandey reported serving on the advisory boards of Roche Diagnostics, Lilly, Cytokinetics, Rivus, Emmi Solutions, and Axon Therapeutics; receiving nonfinancial support from Pfizer and Merck; receiving research grants to his institution from Applied Theraputics, Myovista, and Gilead Sciences; and receiving consulting fees from Tricog Health, Pieces Technologies, and Palomarin.

Comment in

Comment on

References

    1. Reddy YNV, Koepp KE, Carter R, et al. Rate-adaptive atrial pacing for heart failure with preserved ejection fraction: the RAPID-HF randomized clinical trial. JAMA. Published online March 5, 2023. doi: 10.1001/jama.2023.0675 - DOI - PMC - PubMed
    1. Pandey A, Shah SJ, Butler J, et al. Exercise intolerance in older adults with heart failure with preserved ejection fraction. J Am Coll Cardiol. 2021; 78(11):1166–1187. doi: 10.1016/j.jacc.2021.07.014 - DOI - PMC - PubMed
    1. Upadhya B, Pisani B, Kitzman DW. Evolution of geriatric syndrome: pathophysiology and treatment of heart failure with preserved ejection fraction. J Am Geriatr Soc. 2017;65(11):2431–2440. doi: 10.1111/jgs.15141 - DOI - PMC - PubMed
    1. Nassif M, Windsor S, Borlaug B, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954–1960. doi: 10.1038/s41591-021-01536-x - DOI - PMC - PubMed
    1. Solomon SD, McMurray JJV, Claggett B, et al. ; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387 (12):1089–1098. doi: 10.1056/NEJMoa2206286 - DOI - PubMed